Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial is a research paper published in The Prostate (2021). On theSindex it has a DataRank of 1.7. It has been cited 71 times, with 62 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.641
From this paper's citation signal
Citation Network Contribution
1.1
From 44 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 62 citers.
Prostate Cancer Foundation
Grant: Young Investigator Award
Bristol-Myers Squibb
Grant: Investigator Initiated Trial Support
National Institutes of Health
Grant: P30 CA006973
U.S. Department of Defense
Grant: W81XWH‐16‐PCRP‐CCRSA
U.S. Department of Defense
Grant: W81XWH‐19‐1‐0511
FWCI
7.04
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals